I have owned a few shares of LCI for awhile. Their most recent earnings report and writeoff were quite a surprise. Am trying to figure out how bad of shape they are in. Several months ago they hired a new CFO who seems to have great credentials. Sales are down, earnings are down, their pipeline of new products is questionable, they made a major mistake last year in agreement with a supplier, they have invested heavily in new facilities and new enterprise system software. Am hoping the worst is behind and that they have cleaned up the books and are ready to move forward.Any other thoughts. I haven't sold yet, although I have thought about it.
I too have owned LCI for awhile. Unfortunately they have just been sinking lower & lower. As I've watched it go down I have thought often of selling but at the current very low price I'm more inclined to just see what happens. I have even thought of buying a bit more but there is so little news on LCI that I haven't done so. Am hoping the bad news is behind LCI too but generics are having a tough time as are many pharmas. Perhaps there will be some consolidation among generics & LCI will be acquired - a real bargin at this price however not good for shareholder who purchased in the teens though. I'll just wait awhile longer. As I don't have many shares, selling at this price wouldn't yeild much.
I've been in an out of LCI, then got back in when it got down near $3 a share. Its done good since then.Basically it appears they made some mistakes and paid the price. Since then, they have a new CFO, a new board member, a few new approvals, and a new ERP system that may facilitate even more and quicker approvals.I think the new approvals will provide most growth in financial results. It seems they are on the right track, hopefully they will continue.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Ana